July 16, 2024

Rising Blepharitis cases to boost the Blepharitis Treatment Market Growth

Blepharitis Treatment Market

Blepharitis Treatment Market By Therapy Type (Topical antibiotics, Oral antibiotics, Steroids, Others); Drugs (Blephamide, Maxitrol, Dexamethasone, Neomycin, Prednisolone, Cortisporin Ophthalmic Suspension); Distribution Channel (Online Pharmacies, Retail pharmacies, Hospital pharmacies, Others) Geography (North America, Europe, Asia-Pacific, and Rest of the World) Size, Share, Outlook, and Opportunity Analysis, 2023-2030.

The global Blepharitis Treatment Market is estimated to be valued at reach US$ 355.38 million in 2022 and is expected to exhibit a CAGR of 5.08 % over the forecast period, as highlighted in a new report published by Coherent Market Insights. The Blepharitis Treatment market is experiencing significant growth due to the rising prevalence of blepharitis, a common eye condition affecting millions worldwide.

Market Overview:

Blepharitis means infection of the eyelid. The edges of the lids appear red or dark in color and start being swollen and scaly. Blepharitis generally impacts both eyes. It can occur when a skin condition leads to irritation, while one develops an inflammation, or when oil glands become congested. All of these things can be done at once. Blepharitis is a word used for infection, but it can lead to an infection in the eye. Anyhow, most cases of blepharitis are not transmittable. They are not likely to lead to blindness.

Competitive Landscape:

MPS Treatment Advances Market Key players involved in the growth of global Blepharitis Treatment market are Blepharitis F. Hoffmann-La Roche Ltd, Novartis AG, Astrazeneca, Pfizer Inc., Sanofi, Johnson & Johnson Services, Inc., AbbVie Inc., Allergan, Merck & Co., Inc., Amgen Inc., Boehringer Ingelheim International GmbH, CELGENE CORPORATION DAIICHI SANKYO COMPANY, LIMITED., Cardinal Health, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited., GlaxoSmithKline plc, Mylan N.V., Regeneron Pharmaceuticals Inc. and among other domestic and global players.

Market Key Drivers:

The increasing prevalence of Blepharitis is expected to augment the growth of the global Blepharitis Treatment Market. For instance, as per NIH, around 40% of people across the globe suffer from Blepharitis.